Clinical Trial Update: Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating low-dose olanzapine for preventing chemotherapy-induced nausea and vomiting in children and adolescents.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• olanzapine (olanzapine)

Snippet

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Conditions: Chemotherapy-induced Nausea and Vomiting | Phase 3 | Status: UNKNOWN